Exploratory INDs Will Better Serve Large Companies, PDL Exec Says

Exploratory investigational new drug applications will provide a greater benefit to large pharma and biotech companies, Protein Design Labs CEO Mark McDade said at the Biotechnology Industry Organization Windhover conference in Washington, D.C. April 26

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet